Literature DB >> 15772196

Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.

J R Emberson1, P H Whincup, D A Lawlor, D Montaner, S Ebrahim.   

Abstract

OBJECTIVE: To assess whether the extent of primary and secondary coronary heart disease (CHD) prevention in older British men and women differs between patients with and without diabetes.
DESIGN: Two prospective cardiovascular cohort studies.
SETTING: 24 British towns. PATIENTS: 4252 men and 4286 women aged 60-79 years examined between 1998 and 2001. MAIN OUTCOME MEASURES: Use of aspirin, statin, and blood pressure lowering treatment and risk factor control, examined by diabetic status and history of established CHD.
RESULTS: About 20% of the men and 12% of the women had established CHD at age 60-79 years and 7% of the men and 5% of the women had diabetes. In primary CHD prevention, patients with diabetes were more likely to receive CHD risk reducing medications than those without diabetes, but the proportions receiving preventive treatments in both groups were low. In secondary prevention, diabetic and non-diabetic patients received similar levels of treatment, with the exception of angiotensin converting enzyme inhibitors and (for women only) blood pressure lowering treatment, which were more widely used among diabetic patients. There were no clear differences in blood pressure control or cigarette smoking by diabetic status in primary or secondary prevention. Mean total cholesterol concentrations were lower in diabetic patients independently of treatment with statins.
CONCLUSIONS: Despite their exceptionally high CHD risk, many opportunities to reduce CHD risk among patients with diabetes have not been taken.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772196      PMCID: PMC1768806          DOI: 10.1136/hrt.2004.035832

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  Two decades of progress in preventing vascular disease.

Authors:  Salim Yusuf
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

3.  Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.

Authors:  K J Mukamal; R W Nesto; M C Cohen; J E Muller; M Maclure; J B Sherwood; M A Mittleman
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

4.  Twenty year follow-up of a cohort based in general practices in 24 British towns.

Authors:  M Walker; A G Shaper; L Lennon; P H Whincup
Journal:  J Public Health Med       Date:  2000-12

5.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study.

Authors:  D A Lawlor; C Bedford; M Taylor; S Ebrahim
Journal:  J Epidemiol Community Health       Date:  2003-02       Impact factor: 3.710

8.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Low prevalence of lipid lowering drug use in older men with established coronary heart disease.

Authors:  P H Whincup; J R Emberson; L Lennon; M Walker; O Papacosta; A Thomson
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  3 in total

1.  Guidelines and risk factor management.

Authors:  P Primatesta
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

2.  Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Min Zhao; Mark Woodward; Ilonca Vaartjes; Elizabeth R C Millett; Kerstin Klipstein-Grobusch; Karice Hyun; Cheryl Carcel; Sanne A E Peters
Journal:  J Am Heart Assoc       Date:  2020-05-20       Impact factor: 5.501

Review 3.  PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Authors:  Erland Erdmann; John Dormandy; Robert Wilcox; Massimo Massi-Benedetti; Bernard Charbonnel
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.